Loading...
Loading...
LYEL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 5.0M |
| Gross Profit | -5.0M |
| Operating Expense | 51.1M |
| Operating I/L | -56.1M |
| Other Income/Expense | -5.1M |
| Interest Income | 6.8M |
| Pretax | -60.7M |
| Income Tax Expense | 5.0M |
| Net Income/Loss | -60.7M |
Lyell Immunopharma, Inc. is a T cell reprogramming company specializing in developing innovative T cell therapies for patients with solid tumors. The company's technology platforms, including Gen-R and Epi-R, enable the development of T cell therapies to overcome exhaustion and generate durable stemness. Their pipeline includes LYL797 for non-small cell lung cancer and triple negative breast cancers, LYL845 targeting multiple solid tumors, and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Additionally, the company has entered into a research and development collaboration and license agreement with GlaxoSmithKline for the NY-ESO-1 program.
